CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors
Joongwon Choi, Tae Jin Kim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Minyong Kang, Seong Il Seo
Korean J Urol Oncol. 2019;17(3):150-159.   Published online 2019 December 27    DOI: https://doi.org/10.22465/kjuo.2019.17.3.150

Excel Download

Prognostic Significance of Systemic Inflammatory Response in Patients with Synchronous and Metachronous Metastatic Renal Cell Carcinoma Receiving First-Line Tyrosine Kinase Inhibitors
The Korean Journal of Urological Oncology. 2019;17(3):150-159   Crossref logo
Link1 Link2 Link3

Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
SpringerPlus. 2016;5(1):   Crossref logo
Link1 Link2 Link3

Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors
OncoTargets and Therapy. 2013;679   Crossref logo
Link1

Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
International Journal of Urology. 2018;25(6):604-605   Crossref logo
Link1 Link2

Editorial Comment on: Can Tyrosine Kinase Inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
European Urology. 2009;55(6):1439   Crossref logo
Link1 Link2

Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy
Urologic Oncology: Seminars and Original Investigations. 2017;35(9):542.e1-542.e9   Crossref logo
Link1 Link2

Tyrosine kinase inhibitors–induced hypothyroidism as a prognostic factor in metastatic renal cell carcinoma: a systematic review and meta-analysis
. 2020;   Crossref logo
Link1 Link2

Tyrosine kinase inhibitors–induced hypothyroidism as a prognostic factor in metastatic renal cell carcinoma: a systematic review and meta-analysis
. 2020;   Crossref logo
Link1 Link2

Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors
Tumor Biology. 2015;37(4):4919-4927   Crossref logo
Link1 Link2 Link3

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis
BMC Cancer. 2019;19(1):   Crossref logo
Link1 Link2 Link3